GLP-1 Agonists

Sort by:
Relevance Thumbs Up Comments Views Newest Oldest
64:45

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

FEATURING Silvio Inzucchi
  • 39,887 views
  • June 16, 2017
  • 195
15:06

Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

  • 7,715 views
  • August 14, 2023
  • 112
06:31

Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

  • 2,149 views
  • January 26, 2024
  • 40
36:34

Scripps Health

GLP-1 Hysteria

FEATURING Samantha Harris
  • 4,068 views
  • December 8, 2023
  • 31
15:33

Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer Option Compared to Existing Weight Loss Drugs?

  • 7,913 views
  • April 13, 2021
  • 58
12:26

Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

  • 9,716 views
  • April 11, 2022
  • 38
66:59

UT Health San Antonio School of Medicine

Effective Treatment of T2DM Requires Combination Therapy

FEATURING Ralph DeFronzo
  • 2,505 views
  • August 30, 2023
  • 20
20:24

Diana Isaacs

Tirzepatide for Type 2 Diabetes

  • 6,587 views
  • August 23, 2022
  • 44
14:50

Robert Eckel

COVID-19 & Diabetes: How to Manage SGLT2, GLP-1 RAs, Metformin, ACE Inhibitors, ARBs, DPP-4, and Insulin in Hospitalized Pts With Coronavirus? Should We Await for More Research on Hydroxychloroquine Efficacy?

  • 2,515 views
  • May 12, 2020
  • 13
18:43

ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century - Almost

FEATURING Ralph DeFronzo
  • 11,582 views
  • August 12, 2019
  • 58
10:02

Emory Diabetes Education Training Academy

Insulin Treatment in Patients with Type 2 Diabetes: When to Use Combination Therapy

FEATURING Guillermo Umpierrez
  • 3,780 views
  • May 15, 2020
  • 22
25:54

13th Orange County Symposium for Cardiovascular Disease Prevention

SGLT2 inhibitors and GLP-1 agonists: Why Are They Important and Which Do I Choose?

FEATURING Yehuda Handelsman
  • 3,406 views
  • January 27, 2022
  • 15
05:49

Susan Brian

Weight Loss Medications and Menopause

  • 833 views
  • January 9, 2024
  • 12
26:49

Diana Isaacs

Tirzepatide Updates

  • 6,673 views
  • August 29, 2023
  • 41
37:10

Diana Isaacs

Clinical Pearls & Updates on Incretins: The Diabetes Drugs Taking Hollywood by Storm

  • 3,383 views
  • August 29, 2023
  • 19
09:39

ADA 2023 Insights

ADA 2023 Insights: The Effect of Tirzepatide Versus Insulin Degludec on Post Meal Glucose Control in Patients with Type 2 Diabetes (SURPASS-3 CGM)

FEATURING Tadej Battelino
  • 2,754 views
  • August 30, 2023
  • 12
11:31

Domenica Rubino

Weight Loss Maintenance for Adults With Once-Weekly Semaglutide: What Was the Observed Weight Loss Amongst Participants?

  • 1,682 views
  • April 16, 2021
  • 15
05:08

Susan Brian

The Differences Between the Products of GLP1's and GLP/GIPs

  • 2,104 views
  • January 29, 2024
  • 36
27:24

Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

FEATURING Lance Sloan
  • 7,999 views
  • June 17, 2019
  • 48
21:19

The 8th Annual International Hawaii Symposium on Diagnostic and Therapeutic Modalities in Heart Failure

SGLT2 Inhibitors - A New Class of CV Drugs for the Prevention and Treatment of Cardiovascular Disease

FEATURING Gregg Fonarow
  • 1,370 views
  • January 2, 2019
  • 8
28:48

16th Annual Mid-Atlantic Hospital Medicine Symposium

Peri-Operative Medication Management: Anticoagulants, DM & Steroids

FEATURING Dennis Chang
  • 521 views
  • December 15, 2021
  • 2
49:21

McMaster University Department of Medicine

Semaglutide: Where Are We Now and Where Are We Going?

FEATURING Shamma Boushahri, Daniel Lazzam, Kelsey MacEachern
  • 4,129 views
  • September 27, 2023
  • 23
13:28

4th Annual Cardiovascular Conference: Advances in Cardiovascular Disease - from Prevention to Intervention

GLP-1 Agonists: A Review of Within Class Differences for CVD Risk Reduction

FEATURING Alyson Myers
  • 1,108 views
  • April 20, 2021
  • 4
08:03

Jennifer Green

Highlights From ADA 2021: The Pros and Cons of Starting SGLT2 Inhibitors or GLP1-RAs in the Hospital to Reduce the Risk of Adverse CV or Kidney Outcomes

  • 356 views
  • July 14, 2021
  • 3
09:29

Inova Cherry Blossom Cardiovascular Symposium 2022

The Dangerous Intersection of Diabetes and Heart (and Kidney) Disease

FEATURING Darren K. Mcguire
  • 1,954 views
  • August 2, 2022
  • 13

All Topics: